Contrasting Gossamer Bio (GOSS) and The Competition

Gossamer Bio (NASDAQ:GOSS) is one of 844 public companies in the “Biotechnology” industry, but how does it compare to its peers? We will compare Gossamer Bio to similar businesses based on the strength of its institutional ownership, risk, earnings, valuation, dividends, analyst recommendations and profitability.

Volatility & Risk

Gossamer Bio has a beta of 2.21, suggesting that its share price is 121% more volatile than the S&P 500. Comparatively, Gossamer Bio’s peers have a beta of 1.10, suggesting that their average share price is 10% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings for Gossamer Bio and its peers, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gossamer Bio	2	3	5	0	2.30
Gossamer Bio Competitors	9770	15029	45237	1570	2.54

Gossamer Bio presently has a consensus price target of $256.00, indicating a potential upside of 2,366.28%. As a group, “Biotechnology” companies have a potential upside of 93.93%. Given Gossamer Bio’s higher probable upside, analysts clearly believe Gossamer Bio is more favorable than its peers.

Institutional & Insider Ownership

81.2% of Gossamer Bio shares are owned by institutional investors. Comparatively, 47.9% of shares of all “Biotechnology” companies are owned by institutional investors. 4.2% of Gossamer Bio shares are owned by insiders. Comparatively, 13.0% of shares of all “Biotechnology” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares Gossamer Bio and its peers top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Gossamer Bio	$48.47 million	-$170.37 million	-0.19
Gossamer Bio Competitors	$729.84 million	$13.23 million	-10.24

Gossamer Bio’s peers have higher revenue and earnings than Gossamer Bio. Gossamer Bio is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Profitability

This table compares Gossamer Bio and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Gossamer Bio	-235.00%	N/A	-112.04%
Gossamer Bio Competitors	-9,054.31%	-198.21%	-30.53%

Summary

Gossamer Bio peers beat Gossamer Bio on 7 of the 13 factors compared.

Gossamer Bio Company Profile

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.